Personalised Cancer Medicine Flashcards 2025
Indications determined by the organ of origin
Breast Cancer
Standard
Recommended
Currently not recommended
- Estrogen Receptor
- Progesterone Receptor
- HER2
- Genetic platforms: Mammaprint, Oncotype, Prosigna, or Endopredict*
- BRCA 1 and BRCA 2**
- PDL-1***
- PIK3CA****
- NGS*****
- ESR1
- FGFR1
- AKT1
- PTEN
- Liquid biopsy and circulating cancer cells
* in early luminal breast cancer with high risk of relapsing
** in advanced triple negative or luminal breast cancer
*** in advanced triple negative breast cancer
**** in advanced luminal breast cancer
***** Approved in US as companion diagnostics of a PI3K inhibitor
** in advanced triple negative or luminal breast cancer
*** in advanced triple negative breast cancer
**** in advanced luminal breast cancer
***** Approved in US as companion diagnostics of a PI3K inhibitor
The Standard category is based on current treatment indications with approved funding by the Spanish National Health System.
The Recommended category is based on currentrecommendations by EMEA and FDA.
The Recommended category is based on currentrecommendations by EMEA and FDA.
References:
1. Colomer R, González-Farré B, Ballesteros AI, Peg V, Bermejo B, Pérez-Mies B, de la Cruz S, Rojo F, Pernas S, Palacios J. Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2024 Dec;26(12):2935-2951. doi: 10.1007/s12094-024-03541-1
